Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study

Table 2 Patients’ evolution during follow-up: hemoglobin, renal biomarkers and clinical outcomes

Variables	Control	EPO 20’000ui	EPO 40’000ui	P*
Median (25^th-75^thpercentiles)	N = 40	N = 20	N = 20
Hemoglobin R g/l	97.5 (87.5-105.8)	100.5 (92.3-107)	98 (85–107)	0.41
Hemoglobin last g/l	100.5 (96.3-113.8)	100.0 (93–109)	101.5 (90.8-114.8)	0.69
Renal biomarkers
Creatinine R μmol/l	78 (61–98)	94 (74.5-102)	91.5 (67.8-114.3)	0.29
Creatinine 48 h μmol/l	79 (65.8-88.8)	78 (62–98)	82.5 (66–114.5)	0.23
Creatinine 96 h μmol/l	77.5 (63.3-85.8)	75 (65–92)	87 (72.8-100.8)	0.53
Cystatine C Rmg/l	1.1 (0.9-1.4)	1.2 (1.1-1.5)	1.2 (1.0-1.4)	0.60
Cystatine C 48 h - mg/l	1.2 (1.1-1.4)	1.3 (1.1-1.6)	1.3 (1.1-1.6)	0.25
Cystatine C 96 h mg/l	1.3 (1.1-1.4)	1.2 (1.1-1.5)	1.3 (1.1-1.7)	0.80
Urinary Ngal R ng/ml	21 (5.7-44.3)	43.3 (18.3-62.9)	11 (0–76)	0.18
Urinary Ngal 48 h ng/ml	26.8 (12–46.7)	15.7 (2.6-39)	26 (6.2-58.8)	0.47
Clinical outcomes
Hospital stay in days	14.5 (11–21.8)	16.5 (10.8- 26.8)	15.5 (10.3-22.5)	0.96
ICU stay in days	1 (1–3)	2.5 (1.3- 5)	1 (1–3.8)	0.07
Acute Kidney Injury ¤	7 (17.5%)	5 (25%)	6 (30%)	0.53
Death	2 (5%)	1 (5%)	2 (10%)	0.74

*p compares the 3 treatment groups.
R: randomization. 48 h: 48 hours after randomization. 96 h: 96 hours after randomization. ICU: Intensive care Unit.
¤ In stage 1: n = 15; in stage 2: n = 3 (n = 2 in EPO 40’000 and n = 1 in EPO 20’000 groups).

ISSN: 1471-2369